PRF Adds Risk Warnings as Activist S.H.N. Presses Tel Aviv Court for Special Meeting
PRFX sits 18% above its 52-week low of $0.641 on light trading volume (0.3× avg).
Summary
PRF Technologies disclosed a new risk factor after activist S.H.N. petitioned a Tel Aviv court on November 2, 2026 to force a special meeting removing three of five directors and to restrict share issuances, including under its YA II PN standby equity purchase agreement. The company has 20 days to respond.
Key Events · Legal and Risk Events · PRFX
-
Court Petition Over Board Removal
On November 2, 2026, S.H.N. petitioned the Tel Aviv District Court (Economic Division) to order a special general meeting removing PRF's three non-external directors — a majority of the five-member board — and electing three S.H.N. nominees.
-
Interim Relief Would Freeze Capital Raises
S.H.N. seeks interim relief barring actions outside the ordinary course, including asset dispositions and securities issuances under the Standby Equity Purchase Agreement with YA II PN, Ltd., plus a bar on appointing additional directors.
-
Company Has 20 Days to Respond
No court order has been issued on the petition or the interim relief; PRF has 20 days to submit its response unless the court orders otherwise, and says it disputes S.H.N.'s claims and will defend vigorously.
-
Cost and Liability Exposure Flagged
Under Section 65(b) of the Israeli Companies Law, if the court orders the meeting PRF would bear S.H.N.'s reasonable expenses, reimbursable by the responsible directors; S.H.N. also threatened personal liability for directors and office holders.
Analysis · PRFX · Life Sciences
S.H.N. is seeking to replace three of PRF's five directors and has asked the Tel Aviv District Court to force the meeting and, in the meantime, to freeze out-of-the-ordinary actions — including share issuances under the YA II PN standby equity purchase agreement. If granted, that interim relief would cut off a funding channel for a company that reported about $11.0 million of cash against $2.5 million of liabilities at the end of September. The new risk factor also flags that PRF would bear S.H.N.'s reasonable meeting expenses if the court orders the meeting, and that S.H.N. has threatened personal liability for directors. PRF has 20 days to respond and says it will defend its position.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.64 to $7.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.